Evidence map›Paper›PMID 28042310›Full record

ReviewTherapeutic advances in urology2017

Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.

Holger Gerullis, Friedhelm Wawroschek, Claus-Henning Köhne, Thorsten Holger Ecke

Open access · bronzeAbstract readReview
In one paragraph

Review in Therapeutic advances in urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Antibiotics (Basel, Switzerland) · 2022
    Article
  6. Review
  7. Review
  8. Review
  9. Anticancer Potential of Betulonic Acid Derivatives.International journal of molecular sciences · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Holger GerullisUniversity Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Rahel-Straus-Straße 10, 26133 Oldenburg, Germany.
Friedhelm WawroschekUniversity Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Germany.
Claus-Henning KöhneUniversity Hospital of Oncology/Haematology, Oncology Center Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Germany.
Thorsten Holger EckeHELIOS Hospital, Department of Urology, Bad Saarow, Germany.
Klinikum Oldenburg · DEHelios Hospital Bad Saarow · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure of platin-containing therapy. Since approval, the drug has been investigated in few clinical trials. Most of the currently available reports describe experiences with VFL in a daily clinical setting. This review gives a short overview on clinical experiences and clinical trials involving VFL since the approval of this drug in 2009.

Indexed as

metastatic urothelial carcinomamTCCUsecond lineurothelial cancervinflunine

Identifiers

PMID28042310
PMCPMC5167074
OpenAlexW2552075586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.